Skip to content

Med Tech Spiritus Mundi starts trading on London Stock Exchange

Med Tech Spiritus Mundi starts trading on London Stock Exchange
Dino Kurbegovic

Back in 2021, Spiritus Mundi PLC set out plans for an initial public offering (IPO) on the Main Market of the London Stock Exchange (LSE), which has now come full circle.

Namely, this special purpose acquisition vehicle (SPAC) that sought to acquire companies in the clinical diagnostic sector in Europe and Asia will officially begin trading on the LSE as of today, July 8, under the ticker symbol SPMU. 

Further, the listing will consist of 49,300,000 ordinary shares admitted to the Standard Listing segment of the Official List of the Financial Conduct Authority.

In short, the SPAC was established in 2021 by Zaccheus Peh, an experienced entrepreneur in the clinical diagnostics, laboratory services, and medical services businesses. Furthermore, with the company’s board, the SPAC has identified a couple of potential take-over targets; yet, at this moment, they do not have a specific initial acquisition under consideration. 

Watershed moment 

Possible acquisitions, under Chapter 5 of the Listing Rules, will be treated as a reverse takeover, along with any subsequent acquisition or investment by the company, depending on the size and nature of the takeover.   

Zaccheus Peh, Non-Executive Chairman of Spiritus Mundi, said in the announcement:

“I am delighted that Spiritus Mundi is listing on the London Stock Exchange. We believe there are attractive acquisition opportunities in our chosen sectors of laboratory and diagnostic testing, and digital healthcare, particularly in light of how the COVID -19 pandemic has changed the sector dynamics. 

He added: 

“We plan to use Spiritus Mundi as a vehicle to acquire one or more exciting businesses in these areas in order to generate attractive returns for our shareholders.”

On the whole, the company managed to secure funding of over £1.2 million (~$1.44 million) in its pre-IPO stage and is run by two proposed directors that ran a laboratory business with revenue of over $2.7 billion.  

Market participants have an opportunity to get in on the ground floor or rather track the development of the SPAC and jump on board once a potential acquisition target has been made public.  

Buy stocks now with Interactive Broker – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.  

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.